5 ways biotech startups can mitigate risk to grow sustainably in the long run

Omar Khalil
Contributor




Share on Twitter





Omar Khalil is a partner at Santé Ventures, where he focuses primarily on biotechnology and medical technology companies.


The unprecedented explosion of investment in life sciences over the past decade has resulted in incredible new therapies for patients, strong financial returns for companies and an overall increase in translational research, which is critical to advancing the next generation of therapies. It has also led to eye-popping levels of capital raised by early-stage companie

リンク元